Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins

• Status: Recruiting
• Trial end date: 2022-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones. How the gut hormone glucagon-like peptide-2 (GLP-2) and glucose release the triglyceride from the gut is not known. The research team in this study is interested in finding out how teduglutide (a degradation resistant form of GLP-2) ang glucose, given together, release stored triglyceride from the gut by evaluating how blood lipoproteins respond to teduglutide in healthy individuals.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Health Network, Toronto
• Treatments: Teduglutide

Criteria

Inclusion Criteria:

• Men and women, aged 18 to 60 years.

• Body mass index 20 to 27 kg/m2

Exclusion Criteria:

1. Patients with active inflammatory bowel disease

2. Patients with pre-existing Celiac disease, exocrine pancreatic insufficiency or small bowel malabsorption

3. Patients with active bowel malignancy

4. Patients with diabetes mellitus or known/ suspected motility disorders of the gut

5. Patients with decompensated liver disease

6. Patients on ezetimibe or bile acid sequestrants

7. Patients who are pregnant or breastfeeding.

8. Patients with renal disease.

9. Patients on benzodiazepine.

10. Unstable cardiac or respiratory disease

11. Any changes to medication in the preceding month

12. Patients with hypersensitive to Revestive or any ingredient, active or a history of the drug within the last 5 years

13. Patients with GI malignancy (GI tract, hepatobiliary, pancreatic)